News coverage about Calithera Biosciences (NASDAQ:CALA) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 47.2109110407495 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern Sentiment’s analysis:

Several equities research analysts recently commented on CALA shares. BidaskClub downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. William Blair started coverage on shares of Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Monday, November 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $15.17.

Shares of Calithera Biosciences (NASDAQ:CALA) traded up $1.05 during trading hours on Friday, hitting $16.45. 524,000 shares of the company traded hands, compared to its average volume of 715,147. Calithera Biosciences has a fifty-two week low of $2.90 and a fifty-two week high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $6.02 million. research analysts forecast that Calithera Biosciences will post -0.77 earnings per share for the current year.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 16.30% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.